search
Back to results

Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients

Primary Purpose

Rectal Cancer

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Intraoperative Mobile Gamma Camera imaging
Endoscopic injection of 99mTc-sulfur colloid
Endoscopic injections of Spot
Preoperative flexible sigmoidoscopy
SPECT/CT
Sponsored by
University of Virginia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Rectal Cancer focused on measuring sentinel lymph node, lymphatic mapping, rectal tumor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult patients with stage I,II, or III rectal cancer undergoing standard trans- abdominal low anterior resection or abdominoperineal resection surgery at the University of Virginia
  • Willing and able to give written informed consent

Exclusion Criteria:

  • Patients less than 18 years of age
  • Women who are pregnant and/or breastfeeding
  • Prisoners
  • Unable to give written informed consent
  • Participants with medical contradictions or have potential problems complying with the requirements of the protocol, in the opinion of the investigator

Sites / Locations

  • University of Virginia

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Surgery with pre- and intra-op imaging

Arm Description

Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.

Outcomes

Primary Outcome Measures

Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.
The primary endpoint is the sensitivity of sentinel lymph node (SLN) detection by the technique which will be estimated by the number of SLNs detected by the technique divided by the number noted at surgery or on final pathology review. 90% confidences interval around the estimate will help guide interpretation of the results.

Secondary Outcome Measures

Feasibility
Descriptive summaries will be used to list any complications that may have occurred pre-, intra- or post-operatively. Frequency and location of the sentinel lymph node (SLN) with respect to the tumor prior to surgery will be noted. In addition the location of the SLN in relation to the tumor will be documented during pathologic examination with the pathologist and surgeon to assess the feasibility of excision with transanal endoscopic microsurgery.

Full Information

First Posted
March 20, 2014
Last Updated
July 14, 2016
Sponsor
University of Virginia
Collaborators
American Cancer Society, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02112240
Brief Title
Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients
Official Title
Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Withdrawn
Why Stopped
No accrual. New study opening with modified technique.
Study Start Date
May 2013 (undefined)
Primary Completion Date
February 2017 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Virginia
Collaborators
American Cancer Society, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to see if investigators can develop a technique to identify sentinel lymph nodes in the rectum for rectal cancer patients with the use of a radiotracer (Tc-sulfur colloid), a dye (Spot), and imaging, both pre- and intraoperatively. Eligible patients are those with stage I-III rectal cancer undergoing standard low anterior resection or abdominoperineal resection. Investigators hypothesize that use of a unique intraoperative lymphatic mapping technique using a mobile gamma camera will identify the sentinel lymph node in patients with rectal cancer with greater than 80% sensitivity. Subjects will receive injections of the tracer and dye prior to surgery, have preoperative SPECT/CT imaging to be used as a guide to the rectal lymphatic system and then proceed to their scheduled surgery. During surgery, images of the rectum will be taken with a unique mobile gamma camera prior to removal and upon resection. If surgeons are able to identify the sentinel lymph nodes surrounding the rectal tumor, the hope is to combine this technique with a less invasive surgery called transanal endoscopic microsurgery (TEM) for early stage rectal cancer patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer
Keywords
sentinel lymph node, lymphatic mapping, rectal tumor

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Surgery with pre- and intra-op imaging
Arm Type
Experimental
Arm Description
Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.
Intervention Type
Other
Intervention Name(s)
Intraoperative Mobile Gamma Camera imaging
Intervention Description
Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
Intervention Type
Drug
Intervention Name(s)
Endoscopic injection of 99mTc-sulfur colloid
Other Intervention Name(s)
Tc-sulfur colloid
Intervention Description
Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
Intervention Type
Other
Intervention Name(s)
Endoscopic injections of Spot
Intervention Description
Dye injection for tattooing rectal tumor prior to surgical resection.
Intervention Type
Procedure
Intervention Name(s)
Preoperative flexible sigmoidoscopy
Intervention Description
Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
Intervention Type
Radiation
Intervention Name(s)
SPECT/CT
Intervention Description
Preoperative imaging to identify lymph nodes in rectum.
Primary Outcome Measure Information:
Title
Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.
Description
The primary endpoint is the sensitivity of sentinel lymph node (SLN) detection by the technique which will be estimated by the number of SLNs detected by the technique divided by the number noted at surgery or on final pathology review. 90% confidences interval around the estimate will help guide interpretation of the results.
Time Frame
At the time of surgery and the time of pathological review, an expected average of 7 days.
Secondary Outcome Measure Information:
Title
Feasibility
Description
Descriptive summaries will be used to list any complications that may have occurred pre-, intra- or post-operatively. Frequency and location of the sentinel lymph node (SLN) with respect to the tumor prior to surgery will be noted. In addition the location of the SLN in relation to the tumor will be documented during pathologic examination with the pathologist and surgeon to assess the feasibility of excision with transanal endoscopic microsurgery.
Time Frame
From the time of tracer and dye injections to 30 day postoperative visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients with stage I,II, or III rectal cancer undergoing standard trans- abdominal low anterior resection or abdominoperineal resection surgery at the University of Virginia Willing and able to give written informed consent Exclusion Criteria: Patients less than 18 years of age Women who are pregnant and/or breastfeeding Prisoners Unable to give written informed consent Participants with medical contradictions or have potential problems complying with the requirements of the protocol, in the opinion of the investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Traci L Hedrick, MD
Organizational Affiliation
University of Virginia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Virginia
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients

We'll reach out to this number within 24 hrs